Clinical Trial Update: Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports systemic pharmacokinetics after intravitreal injections of an anti-VEGF agent.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Unspecified anti-VEGF intravitreal injection (VEGF inhibitor)

Snippet

Sponsor: California Retina Consultants | Conditions: Age-related Macular Degeneration, Diabetic Macular Edema | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-05-19